Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tobevibart + Elebsiran in Chronic HDV Infection
NCT06903338Phase 3Active, not recruiting
- Sponsor
- Vir Biotechnology
- Start
- Mar 2025
- Primary completion
- Sep 2026
- Modality
- Conjugated siRNA, Monoclonal Antibodies, Chemically Modified siRNA
- Countries
- 10
01
Overview
A Phase 3 trial of tobevibart, elebsiran in chronic hepatitis D, sponsored by Vir Biotechnology. Started Mar 2025; status: active, not recruiting.
02
Drugs
tobevibartelebsiran
03
Conditions
chronic hepatitis D
Beyond the preview
Go deeper on NCT06903338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06903338.